current
advancements in proteomics and other technologies have significantly
accelerated the discovery and development of biomarkers for the
diagnosis and prognosis of prostate cancer and include DNA-based
markers, RNA-based biomarkers, and, particulary, protein biomarkers.
Human prostatic acid phosphatase (PAP) and serum acid phosphatase
(AP) were reportedly the first serum protein biomarkers for prostate
cancer